




Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study

Joanna C. Porter^{1,11}, Thida Win^{2,11}, Kjell Erlandsson³, Francesco Fraioli³, Alaleh Rashidnasab³, Beverley Holman³, Balaji Ganeshan³, Nicholas J. Screatton⁴, Toby M. Maher^{5,6,7}, Raymond Endozo³, John Hoath³, Robert I. Shortman³, Elise Emond³, Kris Thielemans³, Brian F. Hutton³, Pauline T. Lukey⁸, Franklin Aigbirio⁹, Saif Khan¹⁰, Manuel Rodriguez-Justo¹⁰ and Ashley M. Groves³

¹CITR, UCL and Interstitial Lung Disease Centre, UCLH, London, UK. ²Respiratory Medicine, Lister Hospital, Stevenage, UK. ³Institute of Nuclear Medicine, UCL/H, London, UK. ⁴Radiology Dept, Papworth Hospital, Papworth Everard, UK. ⁵Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ⁶Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London, UK. ⁷National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK. ⁸Target to Treatment Consulting Ltd, Stevenage Bioscience Catalyst, Stevenage, UK. ⁹Wolfson Brain Imaging Centre, University Cambridge, Cambridge, UK. ¹⁰Dept of Histopathology, UCLH, London, UK. ¹¹Joint first authors.

Ashley Groves (ashleygroves@nhs.net)



Shareable abstract (@ERSpublications)

This study found no detectable ¹⁸F-MISO signal in fibrotic lung despite some histological expression of hypoxic markers, and concludes that in these IPF patients, the degree of hypoxia is too low to be detectable with ¹⁸F-MISO-PET/CT <https://bit.ly/3wLJwja>

Cite this article as: Porter JC, Win T, Erlandsson K, *et al.* Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study. *Eur Respir J* 2021; 58: 2004584 [DOI: 10.1183/13993003.04584-2020].

This single-page version can be shared freely online.

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org

Received: 5 Jan 2021
Accepted: 4 June 2021

To the Editor:

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease, with an incidence of ~1 per 10 000 per year, and a poor prognosis with limited treatments [1]. The role of hypoxia in disease progression is unclear.